Financhill
Sell
28

PEPG Quote, Financials, Valuation and Earnings

Last price:
$2.17
Seasonality move :
-0.65%
Day range:
$2.29 - $2.46
52-week range:
$1.16 - $19.30
Dividend yield:
0%
P/E ratio:
--
P/S ratio:
--
P/B ratio:
0.65x
Volume:
336.3K
Avg. volume:
5.6M
1-year change:
-84.78%
Market cap:
$76.8M
Revenue:
--
EPS (TTM):
-$2.84

Price Performance History

Performance vs. Valuation Benchmarks

SEE THE 1% OF STOCKS YOU NEED TO OWN FOR MASSIVE RETURNS

GET BETTER TRADE IDEAS

Competitors

Company Revenue Forecast Earnings Forecast Revenue Growth Forecast Earnings Growth Forecast Analyst Price Target Median
PEPG
PepGen
-- -$0.72 -- -19.05% $12.20
CPRX
Catalyst Pharmaceuticals
$134.2M $0.55 33.42% 186.84% $33.33
EWTX
Edgewise Therapeutics
-- -$0.42 -- -27.65% $47.13
RGNX
Regenxbio
$23.7M -$1.08 500.31% -68.12% $32.92
SRPT
Sarepta Therapeutics
$631M $2.06 67.9% 370.14% $178.55
VRTX
Vertex Pharmaceuticals
$2.8B $4.02 5.83% 2.33% $496.78
Company Price Analyst Target Market Cap P/E Ratio Dividend per Share Dividend Yield Price / LTM Sales
PEPG
PepGen
$2.35 $12.20 $76.8M -- $0.00 0% --
CPRX
Catalyst Pharmaceuticals
$21.81 $33.33 $2.6B 16.65x $0.00 0% 5.54x
EWTX
Edgewise Therapeutics
$26.43 $47.13 $2.5B -- $0.00 0% --
RGNX
Regenxbio
$7.00 $32.92 $350.6M -- $0.00 0% 4.16x
SRPT
Sarepta Therapeutics
$101.35 $178.55 $9.8B 44.45x $0.00 0% 5.94x
VRTX
Vertex Pharmaceuticals
$513.76 $496.78 $131.9B 26.10x $0.00 0% 12.09x
Company Total Debt / Total Capital Beta Debt to Equity Quick Ratio
PEPG
PepGen
-- -2.752 -- --
CPRX
Catalyst Pharmaceuticals
-- 0.693 -- 4.83x
EWTX
Edgewise Therapeutics
-- 0.930 -- --
RGNX
Regenxbio
-- 3.452 -- 2.48x
SRPT
Sarepta Therapeutics
42.67% 1.259 9.65% 2.74x
VRTX
Vertex Pharmaceuticals
-- 1.364 -- 2.17x
Company Gross Profit Operating Income Return on Invested Capital Return on Common Equity EBIT Margin Free Cash Flow
PEPG
PepGen
-- -$24.3M -- -- -- -$19.7M
CPRX
Catalyst Pharmaceuticals
$120.2M $62.8M 27.81% 27.81% 44.31% $70.8M
EWTX
Edgewise Therapeutics
-- -$45.5M -- -- -- -$27.2M
RGNX
Regenxbio
$14.9M -$51.4M -70.45% -70.45% -196.89% -$32.7M
SRPT
Sarepta Therapeutics
$526.1M $161.7M 10.04% 20.83% 26.76% $54M
VRTX
Vertex Pharmaceuticals
$2.5B $1.1B -3.23% -3.23% 39.12% $492M

PepGen vs. Competitors

  • Which has Higher Returns PEPG or CPRX?

    Catalyst Pharmaceuticals has a net margin of -- compared to PepGen's net margin of 39.44%. PepGen's return on equity of -- beat Catalyst Pharmaceuticals's return on equity of 27.81%.

    Company Gross Margin Earnings Per Share Invested Capital
    PEPG
    PepGen
    -- -$0.68 --
    CPRX
    Catalyst Pharmaceuticals
    84.74% $0.44 $727.6M
  • What do Analysts Say About PEPG or CPRX?

    PepGen has a consensus price target of $12.20, signalling upside risk potential of 419.15%. On the other hand Catalyst Pharmaceuticals has an analysts' consensus of $33.33 which suggests that it could grow by 52.84%. Given that PepGen has higher upside potential than Catalyst Pharmaceuticals, analysts believe PepGen is more attractive than Catalyst Pharmaceuticals.

    Company Buy Ratings Hold Ratings Sell Ratings
    PEPG
    PepGen
    3 0 0
    CPRX
    Catalyst Pharmaceuticals
    7 0 0
  • Is PEPG or CPRX More Risky?

    PepGen has a beta of 0.000, which suggesting that the stock is 100% less volatile than S&P 500. In comparison Catalyst Pharmaceuticals has a beta of 0.836, suggesting its less volatile than the S&P 500 by 16.449%.

  • Which is a Better Dividend Stock PEPG or CPRX?

    PepGen has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Catalyst Pharmaceuticals offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. PepGen pays -- of its earnings as a dividend. Catalyst Pharmaceuticals pays out -- of its earnings as a dividend.

  • Which has Better Financial Ratios PEPG or CPRX?

    PepGen quarterly revenues are --, which are smaller than Catalyst Pharmaceuticals quarterly revenues of $141.8M. PepGen's net income of -$22.2M is lower than Catalyst Pharmaceuticals's net income of $55.9M. Notably, PepGen's price-to-earnings ratio is -- while Catalyst Pharmaceuticals's PE ratio is 16.65x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for PepGen is -- versus 5.54x for Catalyst Pharmaceuticals. Usually stocks with elevated PS ratios are considered overvalued.

    Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income
    PEPG
    PepGen
    -- -- -- -$22.2M
    CPRX
    Catalyst Pharmaceuticals
    5.54x 16.65x $141.8M $55.9M
  • Which has Higher Returns PEPG or EWTX?

    Edgewise Therapeutics has a net margin of -- compared to PepGen's net margin of --. PepGen's return on equity of -- beat Edgewise Therapeutics's return on equity of --.

    Company Gross Margin Earnings Per Share Invested Capital
    PEPG
    PepGen
    -- -$0.68 --
    EWTX
    Edgewise Therapeutics
    -- -$0.42 --
  • What do Analysts Say About PEPG or EWTX?

    PepGen has a consensus price target of $12.20, signalling upside risk potential of 419.15%. On the other hand Edgewise Therapeutics has an analysts' consensus of $47.13 which suggests that it could grow by 78.3%. Given that PepGen has higher upside potential than Edgewise Therapeutics, analysts believe PepGen is more attractive than Edgewise Therapeutics.

    Company Buy Ratings Hold Ratings Sell Ratings
    PEPG
    PepGen
    3 0 0
    EWTX
    Edgewise Therapeutics
    4 1 0
  • Is PEPG or EWTX More Risky?

    PepGen has a beta of 0.000, which suggesting that the stock is 100% less volatile than S&P 500. In comparison Edgewise Therapeutics has a beta of 0.000, suggesting its less volatile than the S&P 500 by 100%.

  • Which is a Better Dividend Stock PEPG or EWTX?

    PepGen has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Edgewise Therapeutics offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. PepGen pays -- of its earnings as a dividend. Edgewise Therapeutics pays out -- of its earnings as a dividend.

  • Which has Better Financial Ratios PEPG or EWTX?

    PepGen quarterly revenues are --, which are smaller than Edgewise Therapeutics quarterly revenues of --. PepGen's net income of -$22.2M is higher than Edgewise Therapeutics's net income of -$39.7M. Notably, PepGen's price-to-earnings ratio is -- while Edgewise Therapeutics's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for PepGen is -- versus -- for Edgewise Therapeutics. Usually stocks with elevated PS ratios are considered overvalued.

    Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income
    PEPG
    PepGen
    -- -- -- -$22.2M
    EWTX
    Edgewise Therapeutics
    -- -- -- -$39.7M
  • Which has Higher Returns PEPG or RGNX?

    Regenxbio has a net margin of -- compared to PepGen's net margin of -241.28%. PepGen's return on equity of -- beat Regenxbio's return on equity of -70.45%.

    Company Gross Margin Earnings Per Share Invested Capital
    PEPG
    PepGen
    -- -$0.68 --
    RGNX
    Regenxbio
    70.22% -$1.01 $259.7M
  • What do Analysts Say About PEPG or RGNX?

    PepGen has a consensus price target of $12.20, signalling upside risk potential of 419.15%. On the other hand Regenxbio has an analysts' consensus of $32.92 which suggests that it could grow by 370.24%. Given that PepGen has higher upside potential than Regenxbio, analysts believe PepGen is more attractive than Regenxbio.

    Company Buy Ratings Hold Ratings Sell Ratings
    PEPG
    PepGen
    3 0 0
    RGNX
    Regenxbio
    6 1 0
  • Is PEPG or RGNX More Risky?

    PepGen has a beta of 0.000, which suggesting that the stock is 100% less volatile than S&P 500. In comparison Regenxbio has a beta of 1.354, suggesting its more volatile than the S&P 500 by 35.35%.

  • Which is a Better Dividend Stock PEPG or RGNX?

    PepGen has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Regenxbio offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. PepGen pays -- of its earnings as a dividend. Regenxbio pays out -- of its earnings as a dividend.

  • Which has Better Financial Ratios PEPG or RGNX?

    PepGen quarterly revenues are --, which are smaller than Regenxbio quarterly revenues of $21.2M. PepGen's net income of -$22.2M is higher than Regenxbio's net income of -$51.2M. Notably, PepGen's price-to-earnings ratio is -- while Regenxbio's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for PepGen is -- versus 4.16x for Regenxbio. Usually stocks with elevated PS ratios are considered overvalued.

    Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income
    PEPG
    PepGen
    -- -- -- -$22.2M
    RGNX
    Regenxbio
    4.16x -- $21.2M -$51.2M
  • Which has Higher Returns PEPG or SRPT?

    Sarepta Therapeutics has a net margin of -- compared to PepGen's net margin of 24.16%. PepGen's return on equity of -- beat Sarepta Therapeutics's return on equity of 20.83%.

    Company Gross Margin Earnings Per Share Invested Capital
    PEPG
    PepGen
    -- -$0.68 --
    SRPT
    Sarepta Therapeutics
    79.91% $1.50 $2.7B
  • What do Analysts Say About PEPG or SRPT?

    PepGen has a consensus price target of $12.20, signalling upside risk potential of 419.15%. On the other hand Sarepta Therapeutics has an analysts' consensus of $178.55 which suggests that it could grow by 76.17%. Given that PepGen has higher upside potential than Sarepta Therapeutics, analysts believe PepGen is more attractive than Sarepta Therapeutics.

    Company Buy Ratings Hold Ratings Sell Ratings
    PEPG
    PepGen
    3 0 0
    SRPT
    Sarepta Therapeutics
    12 1 1
  • Is PEPG or SRPT More Risky?

    PepGen has a beta of 0.000, which suggesting that the stock is 100% less volatile than S&P 500. In comparison Sarepta Therapeutics has a beta of 0.794, suggesting its less volatile than the S&P 500 by 20.639%.

  • Which is a Better Dividend Stock PEPG or SRPT?

    PepGen has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Sarepta Therapeutics offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. PepGen pays -- of its earnings as a dividend. Sarepta Therapeutics pays out -- of its earnings as a dividend.

  • Which has Better Financial Ratios PEPG or SRPT?

    PepGen quarterly revenues are --, which are smaller than Sarepta Therapeutics quarterly revenues of $658.4M. PepGen's net income of -$22.2M is lower than Sarepta Therapeutics's net income of $159M. Notably, PepGen's price-to-earnings ratio is -- while Sarepta Therapeutics's PE ratio is 44.45x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for PepGen is -- versus 5.94x for Sarepta Therapeutics. Usually stocks with elevated PS ratios are considered overvalued.

    Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income
    PEPG
    PepGen
    -- -- -- -$22.2M
    SRPT
    Sarepta Therapeutics
    5.94x 44.45x $658.4M $159M
  • Which has Higher Returns PEPG or VRTX?

    Vertex Pharmaceuticals has a net margin of -- compared to PepGen's net margin of 31.35%. PepGen's return on equity of -- beat Vertex Pharmaceuticals's return on equity of -3.23%.

    Company Gross Margin Earnings Per Share Invested Capital
    PEPG
    PepGen
    -- -$0.68 --
    VRTX
    Vertex Pharmaceuticals
    85.46% $3.50 $16.4B
  • What do Analysts Say About PEPG or VRTX?

    PepGen has a consensus price target of $12.20, signalling upside risk potential of 419.15%. On the other hand Vertex Pharmaceuticals has an analysts' consensus of $496.78 which suggests that it could fall by -3.31%. Given that PepGen has higher upside potential than Vertex Pharmaceuticals, analysts believe PepGen is more attractive than Vertex Pharmaceuticals.

    Company Buy Ratings Hold Ratings Sell Ratings
    PEPG
    PepGen
    3 0 0
    VRTX
    Vertex Pharmaceuticals
    16 12 1
  • Is PEPG or VRTX More Risky?

    PepGen has a beta of 0.000, which suggesting that the stock is 100% less volatile than S&P 500. In comparison Vertex Pharmaceuticals has a beta of 0.414, suggesting its less volatile than the S&P 500 by 58.629%.

  • Which is a Better Dividend Stock PEPG or VRTX?

    PepGen has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Vertex Pharmaceuticals offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. PepGen pays -- of its earnings as a dividend. Vertex Pharmaceuticals pays out -- of its earnings as a dividend.

  • Which has Better Financial Ratios PEPG or VRTX?

    PepGen quarterly revenues are --, which are smaller than Vertex Pharmaceuticals quarterly revenues of $2.9B. PepGen's net income of -$22.2M is lower than Vertex Pharmaceuticals's net income of $913M. Notably, PepGen's price-to-earnings ratio is -- while Vertex Pharmaceuticals's PE ratio is 26.10x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for PepGen is -- versus 12.09x for Vertex Pharmaceuticals. Usually stocks with elevated PS ratios are considered overvalued.

    Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income
    PEPG
    PepGen
    -- -- -- -$22.2M
    VRTX
    Vertex Pharmaceuticals
    12.09x 26.10x $2.9B $913M

SEE THE 1% OF STOCKS YOU NEED TO OWN FOR MASSIVE RETURNS

GET BETTER TRADE IDEAS

Popular

Is the Market Going to Go Lower?
Is the Market Going to Go Lower?

The last month has been extremely difficult for the stock…

2 Dividend Stocks to Buy in a Recession
2 Dividend Stocks to Buy in a Recession

While many economists and investors initially expected 2025 to be…

Is Ford Stock Undervalued Amid the EV Transition?
Is Ford Stock Undervalued Amid the EV Transition?

There is a lot going on in the electric vehicle…

Stock Ideas

Buy
53
Is AAPL Stock a Buy?

Market Cap: $3.2T
P/E Ratio: 35x

Buy
54
Is NVDA Stock a Buy?

Market Cap: $2.9T
P/E Ratio: 41x

Buy
51
Is MSFT Stock a Buy?

Market Cap: $2.9T
P/E Ratio: 33x

Alerts

Buy
52
RGC alert for Mar 18

Regencell Bioscience Holdings [RGC] is up 73.51% over the past day.

Buy
63
EXOD alert for Mar 18

Exodus Movement [EXOD] is down 3.96% over the past day.

Sell
45
MNPR alert for Mar 18

Monopar Therapeutics [MNPR] is up 0.93% over the past day.

THE #1 STOCK ANALYSIS TOOL
TO MAKE SMARTER BUY AND SELL DECISIONS

Show me the best stock